The basic balance sheet information for FY 2008-2009 is presented below. For a complete discussion of MAPS 2008-2009 fiscal year see Rick Doblin's financial report in MAPS Bulletin Volume 19 number 3. You can also read MAPS' complete IRS Form 990 for 2009 in PDF format.MAPS' total income for FY 2008-2009 was $ 1,206,490. A chart presenting comparative results for the financial years 2001 – 2009 is available in PDF format.
Total expenses were $ 1,393,848 which resulted in a decrease of assets in the amount of $ 187,358. Of these expenses, program services totaled $ 1,180,551 and management and general/fundraising costs were $ 213,297. A chart of all of MAPS expenses for FY 2008-2009 is available in PDF format. The division of expenses in terms of program services, management and general, and fundraising costs is the form required for the IRS Form 990. The expenses in the chart are divided differently, and are categorized as project expenses (subdivided into research and educational projects), operational expenses (some of which are considered program services in the IRS report such as our website and Bulletin expenses, which are educational, and a substantial portion of staff salaries for work on research projects), product sales, and capital expenses. A summary of MAPS income, expenses, and assets is available in PDF format as well. You can also see a breakdown of MAPS staff salaries. Total assets at the end of FY 2008-2009 were $ 853,653. Of these assets, restricted funds amounted to $ 245,948 and unrestricted funds amounted to $ 636,029. Of the unrestricted funds, $50,000 is not liquid and is from the value of a remainder interest that MAPS was given in a $1 million home that will probably come to MAPS in 30 or 40 years. Of the restricted funds, $ 110,800 is for LSD/psilocybin research; $ 21,973 for the Project Start-Up Fund: UMass Amherst (John Gilmore donated $ to enable MAPS to fund initial costs of projects in early stages before other donors are likely to feel the projects are solid enough to justify support, ideally with the fund replenished if projects start); $ 81,530 is for the Jordanian MDMA/PTSD Psychotherapy Study, $ 10,364 for the Marijuana Vaporizer Study (which we have been unable to conduct since NIDA refuses to sell 10 grams for this study), $4,655 for Ibogaine Research (Mexico), $8901 in Staff Retirement funds, $1000 for a Creativity Study, $1000 for a Ketamine Study, $ 1,881 for the Erowid.org Website, and $ 3,256 for Summer Festivals. The restricted funds are summarized on this balance sheet available in PDF format. A listing of all MAPS Projects is also available in both PDF and HTML formats. This year we also provided 3 charts projecting MAPS current fiscal year into the future. These cover our projected expenses, projected project costs, and our projected fiscal position at the end of FY 2009-10.